Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk
ABSTRACT
Rare and low frequency variants are not well covered in most germline genotyping arrays and are understudied in relation to epithelial ovarian cancer (EOC) risk. To address this gap, we used genotyping arrays targeting rarer protein-coding variation in 8,165 EOC cases and 11,619 controls from the international Ovarian Cancer Association Consortium (OCAC). Pooled association analyses were conducted at the variant and gene level for 98,543 variants directly genotyped through two exome genotyping projects. Only common variants that represent or are in strong linkage disequilibrium (LD) with previously-identified signals at established loci reached traditional thresholds for exomewide significance (P<5.0x10 -7 ). One of the most significant signals (P all histologies =1.01x10 -13 ;P serous =3.54x10 
.90) with a previously identified 'best hit' (rs7651446) mapping to an intron of TIPARP. Suggestive associations (5.0x10 -5 >P>=5.0 x10 - 7 ) were detected for rare and low-frequency variants at 16 novel loci. Four rare m i s s e n s e variants were identified (ACTBL2 rs73757391 (5q11.2), BTD rs200337373 (3p25.1), K R T 1 3 r s 1 5 0 3 2 1 8 0 9 ( 1 7 q 2 1 . 2 ) and MC2R rs104894658 (18p11.21)), but only MC2R rs104894668 had a large effect size (OR=9.66). Genes most strongly associated with EOC risk included ACTBL2 (P AML =3.23 x 10 -5
; P SKAT-o =9.23x10 -4 ) and KRT13 (P AML =1.67 x 10 -4 ; P SKAT-o =1.07x10 -5 ),
reaffirming variant-level analysis. In summary, this large study identified several rare and low-frequency variants and genes that may contribute to EOC susceptibility, albeit with possible small effects. Future studies that integrate epidemiology, sequencing, and functional assays are needed to further unravel the unexplained heritability and biology of this disease.
INTRODUCTION
at Mayo Clinic Library on July 7, 2016 http://hmg.oxfordjournals.org/
Downloaded from
Epithelial ovarian cancer (EOC) has a strong heritable component, with an estimated three-fold increased risk among women with a first-degree relative having the disease (1) . The excess familial risk that is not attributed to high penetrance mutations in genes such as BRCA1 and BRCA2 may be due to a combination of common and rare alleles that confer low-to moderate penetrance (2, 3) . Genome-wide association studies (GWAS) of EOC t h a t h a v e b e e n c o n d u c t e d u s i n g m o s t o f t h e s a m p l e s i n c l u d e d i n t h e c u r r e n t i n v e s t i g a t i o n have identified common variants at approximately 22 loci that collectively a c c o u n t for 4% of the estimated heritability (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Few data exist regarding the contribution of rare (minor allele frequency (MAF) <0.5%) and low frequency (MAF 0.5-5%) protein-coding variants to EOC risk. This reflects the fact that protein-coding variants have not been targeted by conventional GWAS(14) despite prediction that their effects could be substantial(15) and imputation is known to be challenging for rare variants(16). Table 1 ). Variants were included as 'fixed' content on the arrays if they occurred at least three times and were seen in two or more of the 16 studies (17). Here, we report the first large-scale genetic association study of uncommon exome-wide variants and EOC risk among nearly 20,000 women (Supplementary Table 2 ).
RESULTS
Of the 98,299 polymorphic variants successfully genotyped as part of EOC case-control set 1 and set between 0.5% and 5%). The majority of these variants were non-synonymous (87%) with 81% missense, 1% nonsense, 4% located in splice sites, and <1% resulting in a frame shift.
Single variant associations
The quantile-quantile (Q-Q) plot of the distribution of test statistics for the comparison of genotype frequencies in cases and controls showed slight inflation in the median test statistics of the likelihood ratio tests (λ=1.15; Supplementary Figure 2 ). This slight inflation may be explained by properties of the likelihood ratio test which make it sensitive to rare variants(18 ) ( Figures 1A and 1B , S u p p l e m e n t a r y Table 3 ).
B r i e f l y , the most statistically significant association was observed at 9p22.2 for a previously identified intronic variant near the BNC2 (basonuclin2) gene(4), rs38114113, with an odds ratio (OR), 95% confidence interval (CI), and P-value of 0. Figure 3A) . The ). A fixed-effect meta-analysis of our study with an imputed dataset from the COGS genotyping initiative (19) also revealed stronger associations for variants located near TIPARP and Figure 3B) . The combined analysis of set 1 and set 2 also confirmed the existence of known common EOC susceptibility alleles or their proxies at 17q12, 8q24.21, 17q21.3, and
LINC00886 (Supplementary
) (Supplementary Table 3 ).
Associations for variants reaching a less stringent threshold (5.0x10 -5 >P>=5.0 x10 Table 5 ).
Eight of 9,600 indels assessed in set 1 only reached a threshold of P<9.0x10 -4 , and only one of these 
Gene-level associations
In combined analysis of Affymetrix-and Illumina-based data, thirteen genes had P-values less than 5x10 -4 for an association with EOC susceptibility overall based on the RAML test(28) (Figure 4) .
Consistency was observed when comparing gene-level findings from RAML to those based on the SKAT-O(29) tests ( Table 2 ). The genes that were most strongly associated with EOC risk using RAML included actin, beta-like 2, ACTBL2 (P AML =3.23 x 10 -5
; P SKAT-o =9.23x10 -4 ) and keratin 13, KRT13
(P AML =1.67 x 10 -4 ; P SKAT-o =1.07x10 -5 ); these genes contained individual variants ( rs73757391 and rs150321809) associated with EOC risk (5.0x10 -5 >P>=5.0x10 -7 ) highlighted in Table 1 . Details regarding the set of rare variants that contributed to gene-level findings for ACTBL2 and KRT13 are summarized in Supplementary Table 6 . ACTBL2 and KRT were also statistically significant in the serous-only analysis after multiple correction testing using a FDR threshold of 15%(30). Of the genes featured in Table 2 , MC2R a l s o contained individual r a r e variants associated with EOC risk (5.0x10 -5 >P>=5.0x10
( Table 1 ). W h e n c o m p a r i n g primary high-grade serous EOC tumors and normal fallopian tube tissues in the TCGA dataset, two of the aforementioned genes were differentially expressed: KRT13 was overexpressed in tumor versus normal tissue (p=0.034) while MC2R was under-expressed (p=0.004), though neither finding was significant after adjustment for multiple comparisons. ) were identified as the most strongly associated genes among all histologies, serous histology, and endometrioid histology, respectively (Supplementary Table 7 ; Supplementary Figure 5 ).
Collectively, all genotyped uncommon variants (MAF<0.05%) explained 4.7% of the phenotypic variation in our subjects (54) . Only 2% (.11/4.7) of this variation c a n b e a t t r i b u t e d t o variants with P< 5.0x10 -5 (Supplemental Methods).
DISCUSSION
We report an EOC risk association analysis of 98,299 variants enriched for rare and low frequency protein-coding changes among nearly 20,000 women using commercially available genotyping arrays. Assuming a disease prevalence of 1.4%, our sample size was adequately powered (~89%) to detect identified; most of these variants were (or were in strong LD with) the previously reported top-ranking variant at the locus. Importantly, sixteen novel loci with low-frequency or rare variants at P<5.0 x10 -5 were detected. Four rare variants were identified (ACTBL2 rs73757391 (5q11.2), BTD rs200337373 (3p25.1), KRT13 rs150321809 (17q21.2), and MC2R rs104894658 (18p11.21)), and gene-level analyses revealed statistically significant associations with variation in three of these genes. These results are consistent with the known landscape of common genetic variation in EOC risk and the utility of multi-marker testing for rare variation. They suggest that the effect sizes of rare coding variants wi t h M A F t h at a r e i n t h e ran ge i n clu d ed on t he ex om e arra ys may be less than 1.35, requiring larger sample sizes and the use of a family-based approach for their discovery. Indeed, recent simulation studies suggest that sample sizes of 60,000-100,000 will be needed to detect small effect sizes for rare variants (MAF<0.5%) when using exome genotyping arrays(31).
Among the four rare variants that were identified, rs73757391, rs200337373, and rs104894658
are non-synonymous and predicted to be damaging. Moreover, according to the ClinVar database(26), BTD rs200337373 (G>A) and MC2R rs104894658 (C>A) are reported to be pathogenic for biotinidase deficiency and adrenocorticotropic hormone (ACTH) resistance observed in familial glucocorticoid deficiency(32), respectively. Importantly, gene-level analysis using different methods highlighted ACTBL2, KRT13, and MC2R as being strongly associated with EOC risk overall and serous disease. Whereas ACTBL2 is a cytoskeletal protein abundantly expressed in vascular smooth muscle cells(33) that has no reported link to cancer, BTD (biotinidase) is a putative biomarker of breast cancer(34), papillary thyroid cancer aggressiveness(35), and lymph node involvement in patients with early stage cervical cancer(36).
In vivo a deficiency of biotinidase affects the expression of central-carbon metabolism genes(37), a pathway important in the development and progression of EOC(38, 39). KRT13 encodes a cytoskeletal protein downregulated in an estrogen receptor (ER) positive ovarian cancer cell line (40) and contributes to breast cancer growth and metastasis through its interaction with estradiol and the selective estrogen receptor modulators, tamoxifen and raloxifene (41) . MCR2 belongs to a family of melanocortin receptors involved in the regulation of food intake, inflammation, skin pigmentation, sexual function, and steroidogenesis, in part by binding to adrenocorticotropic hormone (ACTH) (42, 43) . ACTH-producing ovarian tumors have been reported (44) (45) (46) , but this has been in the context of Cushing's syndrome and non-epithelial ovarian cancers. Taken together, there is biological plausibility to explain some but not all of the current association results.
Independent replication of novel rare variant associations is important but challenging because of the lack of appropriate replication panels. The large COGS EOC meta-GWAS(19) with imputation to Phase I 1000 genome project data was completed after the onset of this study. As a form of replication, we attempted to interrogate this dataset(19) for the most strongly associated novel rare variants. Unfortunately, rare variants and their proxies were not represented in the imputed dataset, precluding the possibility of replication and the opportunity to evaluate associations between germline genotype and gene expression via expression quantitative trait locus analysis. Furthermore, our attempt to replicate associations with rare variants identified in studies of EOC that were much smaller than ours (23-25) did not yield statistically significant findings.
The limited evidence for novel rare or low frequency coding variants at exome-wide levels of significance is consistent with studies of other complex diseases (myocardial infarction(51), Alzheimer's disease (52) , and insulin processing and secretion (53) ) that used these exome genotyping arrays. Published findings across cancer types. The limited evidence for rare or low-frequency coding variants may be expected when using rare variant chips for cohorts or diseases for which they were not originally designed. Integration of sequencing data in very large sample sizes may be an effective strategy for discovering additional rare EOC alleles in the future since the arrays do not provide complete coverage of all functional variants at each locus and the accuracy of imputation for rare variants is suboptimal. Even with such limitations, the current study suggests that rare coding variants with large effects m a y exist, although they did not account for a significant fraction of EOC heritability within our data. In total, rare variants accounted for 4.7% of the phenotypic variation in our subjects (54) with only 2% (.11/4.7) of this variation from variants with P< 5.0x10 -5 (Supplemental Methods). The remaining 98% of variance attributable to rare variants in this study could be due to small effect sizes that did not reach statistical significance. In the absence of opportunities to significantly increase sample sizes, future studies should rely on closer integration of epidemiology and laboratory assays of functional effects to further unravel the etiology of this disease.
MATERIALS AND METHODS

Study Population and Genotyping
Study participants came from 27 independent studies in the international Ovarian Cancer Consortium (OCAC)(55) (Supplementary Table 2 ). In brief, cases were women with pathologicallyconfirmed primary invasive EOC, fallopian tube cancer, or peritoneal cancer, and controls were women without EOC, with at least one ovary intact, and for most studies were frequency-matched to controls on age group and self-reported race. Specimens and data were collected according to protocols approved by local institutional review and ethics boards. Figure 1) .
Genotype data for set 1 are being released into dbGAP per NIH guidelines. , ambiguous gender, relatedness, or genotypes discordant with prior genotypes from the international Collaborative Oncological Gene-Environment Study (iCOGS) genotyping array(19). Genotyping also included HapMap DNA samples (CEU, n=95; YRI, n=82; JPT+CHB, n=93), and ancestry was assessed using the IBS matrix for all samples combined with HapMap samples over the uncorrelated variants. Using this multi-dimensional scaling on a weighted identity by state matrix, non-European samples at a distance of greater than 10% were excluded (n=97) (Supplementary Figure   1) . Of the 247,870 markers on the Illumina array, we excluded 94,231 variants (38%) for reasons including call rate <95%, poor cluster separation, duplicate probes, monomorphism, and deviation from HWE (Supplementary Figure 1) . We tested for HWE using a Robertson and Hill test statistic stratified by study (60) and an exact test. Variants that failed both tests were excluded using exclusion thresholds of pvalues < 10 - for cases and controls, respectively. After all exclusions there were 7,046
European ancestry samples (1,878 cases and 5,168 controls) and 153,639 variants genotyped on the Illumina platform (Supplementary Figure 1) . Thirty-five samples were genotyped in common as part of set Thus, a combined total of 18,081 unique subjects of European ancestry (7,308 cases, 10,773 controls)
were genotyped and passed sample QC. Of the 18,081 subjects, 5,138 (997 cases and 4,141 controls) were not previously genotyped as part of a previously described EOC GWAS or post-GWAS initiative (4, 5, 19) .
Of the variants passing QC for each set, 98,543 were present on both platforms and available for pooled analysis (Supplementary Figure 1) , excluding non-autosomal variants (n=1,983) and those with discordant B allele frequencies between the two sets (n=32). On this combined dataset, we carried out principal components analysis (PCA) to examine the sub-European population structure using a linkagedisequilibrium-pruned set of 27,335 autosomal markers with MAF>1% and HWE P value > 10 -7
. We inspected the first 10 principal components (PC) for evidence of population stratification in the pooled samples.
Single Variant Analysis
Each variant was tested for a per allele association with EOC risk using a likelihood ratio test comparing the deviance (-2 × log-likelihood) of two generalized linear models with and without the variant. Models were adjusted for set (1 versus 2) and the first five PCs representing sub-European ancestry. When adjusted for study alone, there was an inflation of the test statistics (λ = 1.20, λ1000 = 1.024) which was reduced to λ = 1.15, (λ1000 = 1.018) after adjustment for five principal components (61) .
Visual inspection of intensity cluster plots resulted in the elimination of 244 variants with poor differentiation between heterozygote and homozygote calls (Supplementary Figure 1) . Subgroup analysis was conducted for the two most common histologic subtypes: serous and endometrioid. Using a stringent Bonferroni correction for 98,299 tests, we considered variants with P<5.0x10 -7 to be statistically significant. Because of the greater number of variants and samples in set 1, we also explored associations for 80,178 variants from set 1 that passed visual cluster inspection and were not included in the Illumina array; for these analyses, we adjusted for the first 3 PCs. Similarly, we also conducted gene-level analysis with the larger set of variants in set 1 which totaled 15,042 genes and 128,992 variants. For genes that were most strongly associated with EOC susceptibility, we mined publicly available gene expression data from the Cancer Genome Atlas Project (TCGA)(65) and compared gene expression between 568 high-grade serous ovarian tumors and 10 normal fallopian tube tissues according to previously described methods (9) . 
